Showing 1481-1490 of 5771 results for "".
- Visgenx Announces Positive Results from a Key Translational Study for its Gene Therapy Candidate for Dry AMDhttps://modernod.com/news/visgenx-announces-positive-results-from-a-key-translational-study-for-its-gene-therapy-candidate-for-dry-amd/2481700/Visgenx announced positive data from a non-human primate study. The translational study used a single subretinal injection to deliver VGX-0111 (carrying an ELOVL2 transgene) to investigate whether VGX-0111 expresses in the target tissues and causes an increase in certain very long chain
- Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Activehttps://modernod.com/news/dopavision-provides-clinical-trial-update-and-announces-all-myopiax-1-trial-sites-are-active/2481699/Dopavision announced an update on its MyopiaX-1 trial (NCT04967287). All clinical trial centers are now open and are actively screening and enrolling study participants, providing trial access to eligible children with myopia across Germany, Spain, the Netherlands, and the United Kingdom.
- Myra Vision Announces Funding to Advance Calibreye Surgical Treatment for Glaucoma Patientshttps://modernod.com/news/myra-vision-raises-money-to-advance-calibreye-surgical-treatment-for-glaucoma-patients/2481694/Myra Vision, which is a Shifamed portfolio company, announced the closing of its $25 million Series B financing to further product development, scale manufacturing capabilities, and support first-in-human investigation of the company's Calibreye System, a novel treatm
- Euclid Announces ABB Optical Group as Licensed Manufacturer and Distributor of Euclid Ortho-K Lenseshttps://modernod.com/news/euclid-announces-abb-optical-group-as-licensed-manufacturer-and-distributor-of-euclid-ortho-k-lenses/2481691/Euclid Vision has announced that ABB Optical Group is now a licensed manufacturer and distributor of the company’s Ortho-K lenses. Financial terms of the deal were not disclosed. ABB, which Euclid says is the largest distributor of soft lenses in the United States,
- EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret in Wet AMD and DMEhttps://modernod.com/news/eyebio-announces-first-patients-dosed-in-phase-1b2-trial-of-restoret-in-wet-amd-and-dme/2481675/Eyebiotech announced the dosing of the first participants in its phase 1b/2 AMARONE (Anti-permeability Mechanism and Age-Related Ocular Neovascularization Evaluation) clinical trial in patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The AMARONE tria
- Alcon Announces Results of the Alcon Eye On Cataract Surveyhttps://modernod.com/news/alcon-announces-results-of-the-alcon-eye-on-cataract-survey/2481672/Alcon announced the results of the Alcon Eye On Cataract Survey, which was conducted between March and April 2023 in Australia, Brazil, China, Germany, India, Italy, Japan, Spain, South Korea and the United States. The survey set out to evaluate vision and cataract insights among the wo
- Ocular Therapeutix Announces 12-Month Topline Data from Ongoing Phase 1 Trial Evaluating OTX-TKI for Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-12-month-topline-data-from-ongoing-phase-1-trial-evaluating-otx-tki-for-wet-amd/2481669/Ocular Therapeutix announced 12-month data from its phase 1 US clinical trial evaluating OTX-TKI, the company’s axitinib intravitreal hydrogel implant, for the treatment of wet age-related macular degeneration (AMD). OTX-TKI is also being developed for the treatment of diabetic retinop
- MediPrint Ophthalmics Announces Results from its SIGHT-2 Phase 2b Group 1 Clinical Studyhttps://modernod.com/news/mediprint-ophthalmics-announces-results-from-its-sight-2-phase-2b-group-1-clinical-study/2481665/MediPrint Ophthalmics announced it has completed its SIGHT-2 dose-finding phase 2b Group 1 (low dose) study for its proprietary drug-eluting contact lens for glaucoma. This is the first of potentially three doses in the second study of its clinical program SIGHT (Sustained Innovati
- Bausch + Lomb Announces New Scientific Data and Analyses Featuring Consumer, Vision Care and Pharmaceuticals Will Be Presented During Optometry's Meetinghttps://modernod.com/news/bausch-lomb-announces-new-scientific-data-and-analyses-featuring-consumer-vision-care-and-pharmaceuticals-will-be-presented-during-optometrys-meeting/2481662/Bausch + Lomb announced that researchers will present the results of 11 scientific poster presentations involving the company’s consumer, vision care and pharmaceutical products during the American Optometric Association (AOA) Optometry’s Meeting e-posters virtual event, which is taki
- Pixium Vision Announces Receipt of € 1.8 Million from the French Government as Research Tax Credithttps://modernod.com/news/pixium-vision-announces-receipt-of-eur-18-million-from-the-french-government-as-research-tax-credit/2481661/Pixium Vision SA announced that it has received a €1.8 million Research Tax Credit from the French government. This cash injection will help extend the company’s cash runway until the end of September 2023, providing more flexibility to pursue its longer-term f